Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00214253 · ClinicalTrials.gov registry record · Phase 1

Islet Transplantation in Type 1 Diabetic Patients

A Phase 1 study of Type 1 Diabetes, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
1
Study location

NCT00214253: Completed Phase 1 study of Type 1 Diabetes, sponsored by University of Wisconsin, Madison.

NCT00214253 is a Phase 1 study of Type 1 Diabetes that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 14 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00214253, a Phase 1 study of Type 1 Diabetes, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

Our hypothesis is that a successful clinical islet transplant program can be established at the University of Wisconsin using a steroid -free, sirolimus- and low dose tacrolimus - based immunosuppressive drug regimen (Edmonton protocol). We intend to answer the following research questions: 1) will treatment of islet transplant recipients with thiazolidinediones (i.e. pioglitazone) enhance post-transplant islet function and reduce the number of islets necessary to achieve adequate metabolic control? 2) which type 1 diabetic patients are optimal candidates for islet transplantation (i.e. islet transplant alone or islet after kidney transplantation)? 3) Can cadaver donor pancreases, which are ordinarily discarded and not used for pancreas transplantation be used for islet transplantation?

Conditions Studied

Type 1 Diabetes

Interventions

  • DRUG Thiazolidinedione

Study Locations (1)

Wisconsin

  • University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2002-02
Est. Completion 2011-10
Phase Phase 1
University of Wisconsin, Madison

1,039 total trials

What the finished NCT00214253 record still lists

NCT00214253 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Thiazolidinedione is the first listed.

NCT00214253 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT00214253 about?

NCT00214253 is a clinical study titled "Islet Transplantation in Type 1 Diabetic Patients". Our hypothesis is that a successful clinical islet transplant program can be established at the University of Wisconsin using a steroid -free, sirolimus- and low dose tacrolimus - based immunosuppressive drug regimen (Edmonton protocol). We intend to answer the following research questions: 1) will ...

What is the current status of trial NCT00214253?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2002-02. Estimated completion is 2011-10.

What conditions does trial NCT00214253 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT00214253?

The interventions under investigation include: Thiazolidinedione (DRUG).

Who is sponsoring clinical trial NCT00214253?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00214253 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00214253's enrollment target sits among peer trials

14 170th of 198 higher than 27 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00214253, the US trial registry maintained by the National Library of Medicine. NCT00214253 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.